by Clinical Neuropsychologist | Wednesday, May 22, 2024 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | May 22, 2024 Wiley: Alzheimer’s & Dementia: Table...
by Clinical Neuropsychologist | Tuesday, May 21, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) pathology is defined by β-amyloid (Aβ) plaques and neurofibrillary tau, but Lewy bodies (LBs; 𝛼-synuclein aggregates) are a common co-pathology for which effective biomarkers are needed. METHODS A validated...
by Clinical Neuropsychologist | Monday, May 20, 2024 | Dementia
Abstract INTRODUCTION Sleep disturbances are common in Alzheimer’s disease (AD) and may reflect pathologic changes in brain networks. To date, no studies have examined changes in sleep functional connectivity (FC) in AD or their relationship with network...
by Clinical Neuropsychologist | Friday, May 17, 2024 | Dementia
Abstract INTRODUCTION Plasma biomarkers of Alzheimer’s disease and related dementias predict global cognitive performance and decline over time; it remains unclear how they associate with changes in different dementia syndromes affecting distinct cognitive...
by Clinical Neuropsychologist | Friday, May 17, 2024 | Dementia
Abstract BACKGROUND Compromised autophagy, including impaired mitophagy and lysosomal function, plays pivotal roles in Alzheimer’s disease (AD). Urolithin A (UA) is a gut microbial metabolite of ellagic acid that stimulates mitophagy. The effects of UA’s...
by Clinical Neuropsychologist | Thursday, May 16, 2024 | Dementia
Abstract INTRODUCTION This study investigates the effect of apolipoprotein E (APOE) genotype on neurology plasma biomarkers in cognitively healthy Super-Seniors. METHODS Three hundred seventy plasma specimens from Super-Senior participants ≥ 85 years old, who have...
